
<!DOCTYPE html>

<html lang="en">
<head>
	<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
	<meta name="viewport" content="width=device-width, initial-scale=1">
	<title></title>
	<link rel="stylesheet" href="css/ef.css" type="text/css" />
	<link rel="stylesheet" href="css/animate.css" type="text/css" />
	<script type="text/javascript" src="js/base.js"></script>
	<script type="text/javascript" src="js/Common.js"></script>
	<script type="text/javascript" charset="utf-8">
		
		var ANIMATION = [
		];
		
	</script>
</head>
<body class="slide-1">

<div id="content">
<div class="blueoverlay"></div>

<header>
<strong>Study 730</strong><br>
KALETRA QD vs BID in ARV-naïve patients

</header>

<div class="headerborder"></div>
<div class="logo"></div>

<section>

<p>An open-label, randomized, multicenter, phase 3 study of KALETRA dosed once daily (QD) vs twice daily (BID) + tenofovir disoproxil fumarate (TDF) 300 mg emtricitabine/(FTC) 200 mg<br>in ARV-naïve patients.<sup>2</sup></p>
<p><strong>Primary endpoint</strong></p>
<p class="bullet">Proportion of patients with HIV-1 RNA &lt;50 copies/mL at week 48, intent-to-treat, non-completer=failure (ITT, NC=F) with a pre-specified non-inferiority margin of 12%.</p>
<p><strong>Safety Considerations</strong></p>
<p class="bullet">In Study 730, the most common moderate to severe adverse events (occurring in <span class="symbol">≥</span>2% of patients) were diarrhea, nausea, vomiting, and headache. Other common adverse events reported in KALETRA clinical trials include abdominal pain, asthenia, and dyspepsia.</strong></p>
<p><strong>Once-daily dosing considerations</strong></p>
<p class="bullet">Do not administer once-daily KALETRA in pediatric patients; in adult patients with three or more lopinavir<br>resistance-associated substitutions; or in combination with efavirenz, nevirapine, nelfinavir,<br>carbamazepine, phenobarbital or phenytoin.</strong></p>
<p class="bullet">Patients should be informed that there may be a greater chance of developing diarrhea with the once-daily<br>regimen as compared with the twice-daily regimen.</strong></p>



</section>

<div class="buttonwrap">
    <button onclick="makecall('PopupWithHeader',Array('EF-01-popup-01','Study Design','<table width=\'700px\'><tr align=\'center\'><td class=\'reference\'>730 Study Design<sup>2</sup></td></tr></table>','90','625','10','0','700','545','1','0','1','0'));">Study Design</button>
    <button onclick="makecall('PopupWithHeader',Array('EF-01-popup-02','Baseine Values','<table width=\'760px\'><tr align=\'center\'><td class=\'reference\'>730 Baseline Values<sup>2</sup></td></tr></table>','230','625','10','0','760','545','1','0','1','0'));">Baseline Values</button>
</div>

<footer>Please click buttons above for Indication and Important Safety Information about KALETRA.</footer>


</div>
</body>
</html>